Best deal of the week
DR. DOPING

Instructions

Logo DR. DOPING

Instruction for use: Amixin

I want this, give me price

Dosage form: Substance; Coated tablets; Film-coated tablets

Active substance: Tiloronum

ATX

J05AX Other antivirals

Pharmacological groups

Antiviral immunostimulating agent - inducer of interferon formation [Antiviral (excluding HIV) means]

Antiviral immunostimulating agent - inducer of interferon formation [Interferon inductors]

The nosological classification (ICD-10)

A55 Chlamydial lymphogranuloma (venereal): Venereal lymphogranuloma; Lymphogranuloma inguinal; Lymphogranuloma chlamydial; Venereal granuloma; Chlamydial lymphogranuloma; Venereal Lymphopathy; Venereal lymphogranulomatosis; Inguinal lymphogranuloma; The fourth venereal disease; Nicola Favra disease; Subacute inguinal purulent microporadenitis; Inguinal lymphogranuloma (inguinal ulceration, inguinal lymphogranulomatosis)

A56 Other chlamydial diseases, sexually transmitted infections: Chlamydial infections; Chlamydia; Tropical bubo

A74 Other diseases caused by chlamydiae

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B02 Shingles [herpes zoster]: Herpes zoster; Herpes zoster; Shingles Herpes; Localized shingles; Infection caused by the herpes zoster virus; Shingles

B15 Acute hepatitis A: Botkin's disease; Viral hepatitis A; Hepatitis A; Infectious hepatitis; Acute hepatitis; Acute viral hepatitis A; Subacute hepatitis; Lightning-fast hepatitis

B16 Acute hepatitis B: Viral hepatitis B; Hepatitis B; Acute hepatitis; Vaccination against hepatitis B; Subacute hepatitis; Acute viral hepatitis B; Acute lingering hepatitis B

B17 Other acute viral hepatitis

B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection

B25 Cytomegalovirus: Generalized CMV infection in patients with AIDS; Cytomegalovirus infection in patients with impaired immunity; Cytomegalovirus infection; Cytomegalovirus infection in patients with habitual miscarriage Cytomegalovirus retinitis; Cytomegalovirus retinitis in AIDS patients; CMV; CMV in AIDS patients; CMV infection; CMV infection in the presence of immunodeficiency; CMV infection in cancer patients with immunosuppression; CMV-pneumonia; CMV retinitis in patients with weakened immunity; CMV retinitis in AIDS patients

G04 Encephalitis, myelitis and encephalomyelitis: Disseminated acute encephalomyelitis; Leukoencephalitis; Meningomielitis; Myelitis; Acute encephalitis; Acute encephalomyelitis; Chronic encephalitis; Chronic encephalomyelitis; Encephalitis; Encephalomyelitis; Inflammation of meninges

G04.8 Other encephalitis, myelitis and encephalomyelitis: Parotent meningoencephalitis; Uveoencephalitis

G35 Multiple Sclerosis: Disseminated Sclerosis; Multiple sclerosis; Recurrent multiple sclerosis; Secondary-progressive multiple sclerosis; Exacerbation of multiple sclerosis; Mixed forms of multiple sclerosis

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

Composition

Tablets, coated with a film membrane 1 tab.

active substance: Tilorone 60 mg; 125 mg

Excipients

Core: potato starch - 25.5 / 46 mg; MCC - 60/120 mg; Povidone-K30 (kollidon 30) - 1,5 / 3 mg; Calcium stearate - 1,5 / 3 mg; Croscarmellose sodium (impellosis) - 1,5 / 3 mg

Film membrane: hypromellose (hydroxypropylmethylcellulose) - 3.405 / 6.81 mg; Titanium dioxide - 1.7815 / 3.563 mg; Macrogol-4000 (polyethylene glycol-4000) - 0.4565 / 0.913 mg; Polysorbate 80 (Tween 80) 0.057 / 0.14 mg; Dye quinoline yellow (E104) - 0.1235 / 0.247 mg; Dye "Sunset Sunset" yellow (E110) - 0.1765 / 0.353 mg

Pharmachologic effect

Mode of action - antiviral, immunomodulating.

Dosing and Administration

Inside, after a meal.

Adults (over 18 years)

Treatment of influenza and other SARS - 125 mg / day for the first 2 days of treatment, then - 125 mg after 48 hours. The course - 750 mg (6 tables).

Prevention of influenza and other ARVI - 125 mg once a week for 6 weeks. The course - 750 mg (6 tables.).

For treatment of herpetic, CMV infection - the first two days of 125 mg, then 48 hours at 125 mg. The course dose is 1.25-2.5 g (10-20 tablets).

Nonspecific prophylaxis of viral hepatitis A - 125 mg once a week for 6 weeks.

Treatment of viral hepatitis A - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course is 1.25 g (10 tablets).

Treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, the course of treatment - 2 g (16 table). With prolonged course of hepatitis B, 125 mg twice a day on the first day, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets).

In chronic hepatitis B - the initial phase of treatment (2.5 g - 20 tablets): the first two days, 125 mg twice a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g to 10 tablets up to 2.5 g - 20 tablets): 125 mg per week. The course dose of the drug Amiksin from 3.75 g to 5 g, the duration of therapy 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

Acute hepatitis C - 125 mg / day for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets).

In chronic hepatitis C - the initial phase of treatment (2.5 g - 20 tablets): the first two days 125 mg twice a day, then 125 mg after 48 hours. Continuation phase (2.5 g - 20 tablets): For 125 mg per week. The course dose of the drug Amiksin - 5 g, the duration of therapy - 6 months, depending on the results of biochemical, immunological, morphological markers of activity of the process.

Complex therapy of neuroviral infections - 125-250 mg / day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

Urogenital and respiratory chlamydia - the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 g (10 tablets).

With the complex therapy of pulmonary tuberculosis - 250 mg the first two days of treatment, then 125 mg after 48 hours. The course dose is 2.5 g (20 tablets).

Children over 7 years old

In uncomplicated forms of influenza and other acute respiratory viral infections, 60 mg once a day on days 1, 2 and 4 from the start of treatment. The course dose is 180 mg (3 tablets).

When complications of influenza or other acute respiratory viral infections occur, 60 mg once a day on the 1st, 2nd, 4th and 6th days from the beginning of treatment. The course dose is 240 mg (4 tables).

Release form

Tablets, film-coated 60 mg, 125 mg. By 6 or 10 tables. In a planar cell package; On 6, 10 or 20 tab. In the polymer bank.

1 or 2 contourcell packs or 1 can of polymer is placed in a pack of cardboard.

Manufacturer

OJSC "Pharmstandard-Tomskkhimpharm". Russia

Conditions of supply of pharmacies

Without a prescription - tablets covered with a film coating, 125 mg.

Prescription - film-coated tablets, 60 mg.

Storage conditions of the drug Amixin

In a dry, the dark place at a temperature of no higher than 30 C.

Keep out of the reach of children.

The shelf life of the drug Amixin

3 years.

Do not use beyond the expiration date printed on the package.

Someone from the USA - just purchased the goods:
Zhenoluten intensive course 180 capsules